CD8A and myeloid sarcoma: The fact that both analysed alleles expand public T-cell clones, but only the more focused HLA-A∗03:01 expanded CD8+ T cells lead to a detectable clinical benefit should also be a topic of future studies concerning the role of different T-cell lineages in MS pathology.